Pharma Update

Tecentriq: First PD-1/L1 with subcutaneous formulation Improving convenience for patients, saving resources for healthcare systems SC administration time (in minutes) Tecentriq performance update • Reaching peak share in first-in-class indications (SCLC, HCC) US/EU launch in adjuvant NSCLC ongoing Roche TECENTRIQ atezolizumab A HT SC 7 -77% • Tecentriq SC: Great Britain approval in August Ot 即 IV 30 News August 30, 2023 Roche wins first approval for subcutaneous Tecentriq The subcutaneous formulation of Tecentriq has been approved in the UK for all indications that its intravenous counterpart has received approval. By Phalguni Deswal Outlook • • Tecentriq SC: CHMP opinion expected in Q4; US approval delayed to 2024 ⚫ Ph III (IMvoke010) Tecentriq in adj SCCHN results expected in Q4 • . Ph III (SKYSCRAPER-01) Tecentriq + tiragolumab final OS results in 1L PD-L1+ NSCLC expected in Q4/Q1 ⚫ Ph III (SKYSCRAPER-14) Tecentriq + tiragolumab in 1L HCC initiated Ph III (IMbrave050) in adj. HCC met primary endpoint RFS, OS immature Potential for LES: Ph III in adjuvant SCCHN and pivotal tiragolumab combination program ongoing CER-Constant Exchange Rates; SC-subcutaneous; NSCLC=non-small cell lung cancer; HCC-hepatocellular cancer; SCLC-small cell lung cancer; SCCHN-squamous cell carcinoma of head and neck; OS-overall survival; LE=line extensions; SC with Halozyme's rHuPH20/ Halozyme's human hyaluronidase 4 54

View entire presentation